[TAB]
1) Augustin M, Herberger K, Hintzen S et al. Prevalence of skin lesions and
need for treatment in a cohort of 90880 workers. Br J Dermatol 2011; 165(4): 865-873
2) Parisi R, Symmons DP, Griffiths CE, Ashcroft DM, on behalf of the
Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project
team. Global Epidemiology of Psoriasis: A Systematic Review of Incidence and
Prevalence. J Invest Dermatol 2012 Sep 27 [Epub ahead of print]
3) Ortonne JP, Prinz JC. Alefacept: a novel and selective biologic agent for the
treatment of chronic plaque psoriasis. Eur J Dermatol 2004; 14: 41-45
4) Augustin M and The European Expert Working Group for Healthcare in Psoriasis.
A framework for improving the quality of care for people with psoriasis. JEADV 2012,
26 (Suppl. 4), 1-16
5) The Psoriasis Association. Disponible en:
http://www.psoriasis-association.org.uk/pages/view/about-psoriasis Ultimo acceso
en octubre de 2012
6) The Psoriasis Association. Disponible en:
http://www.psoriasis-association.org.uk/pages/view/about-psoriasis/types-of-psoriasis/plaque
Ultimo acceso en octubre de 2012
7) Rapp SR, Feldman SR, Exum ML et al. Psoriasis causes as much disability as
other major medical diseases. J Am Acad Dermatol 1999; 41: 401-407
[FTAB]
*La ayuda financiera para el Mandato de Soriasis y los debates en mesa redonda y apoyo escrito para el Documento Sobre la Soriasis se han suministrado a través de Janssen, y más específicamente por medio de Janssen Pharmaceutica NV, Bélgica.
[TAB]
Video:
http://www.multivu.com/mnr/53825-world-psoriasis-day
[FTAB]
CONTACTO: Si desea más información contacte con: Laura Dobell, JanssenEMEA, Teléfono: +44(0)1494-658-151, E-mail: ldobell@its.jnj.com; JoannaSullivan, Publicis Life Brands Resolute, Teléfono: +44(0)207-397-7485,E-mail: joanna.sullivan@publicislifebrandsresolute.com